vs
Guardant Health, Inc.（GH）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
Guardant Health, Inc.的季度营收约是BRC Group Holdings, Inc.的1.5倍（$281.3M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs -45.7%，领先93.6%），Guardant Health, Inc.同比增速更快（39.4% vs -21.9%），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs -15.4%）
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
GH vs RILY — 直观对比
营收规模更大
GH
是对方的1.5倍
$188.3M
营收增速更快
GH
高出61.2%
-21.9%
净利率更高
RILY
高出93.6%
-45.7%
两年增速更快
GH
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $281.3M | $188.3M |
| 净利润 | $-128.5M | $90.3M |
| 毛利率 | 64.6% | 79.5% |
| 营业利润率 | -43.0% | 32.3% |
| 净利率 | -45.7% | 47.9% |
| 营收同比 | 39.4% | -21.9% |
| 净利润同比 | -15.8% | 1710.8% |
| 每股收益（稀释后） | $-1.01 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHRILY
| Q4 25 | $281.3M | $188.3M | ||
| Q3 25 | $265.2M | $215.3M | ||
| Q2 25 | $232.1M | $188.2M | ||
| Q1 25 | $203.5M | $197.2M | ||
| Q4 24 | $201.8M | $241.0M | ||
| Q3 24 | $191.5M | $225.5M | ||
| Q2 24 | $177.2M | $256.0M | ||
| Q1 24 | $168.5M | $263.4M |
净利润GHRILY
| Q4 25 | $-128.5M | $90.3M | ||
| Q3 25 | $-92.7M | $91.1M | ||
| Q2 25 | $-99.9M | $139.5M | ||
| Q1 25 | $-95.2M | $-10.0M | ||
| Q4 24 | $-111.0M | $-5.6M | ||
| Q3 24 | $-107.8M | $-284.4M | ||
| Q2 24 | $-102.6M | $-433.6M | ||
| Q1 24 | $-115.0M | $-49.2M |
毛利率GHRILY
| Q4 25 | 64.6% | 79.5% | ||
| Q3 25 | 64.7% | 83.7% | ||
| Q2 25 | 65.0% | 81.3% | ||
| Q1 25 | 63.3% | 81.4% | ||
| Q4 24 | 61.6% | 79.8% | ||
| Q3 24 | 61.1% | 82.1% | ||
| Q2 24 | 59.1% | 84.5% | ||
| Q1 24 | 61.2% | 85.3% |
营业利润率GHRILY
| Q4 25 | -43.0% | 32.3% | ||
| Q3 25 | -37.3% | 30.4% | ||
| Q2 25 | -45.9% | 5.7% | ||
| Q1 25 | -54.6% | -31.2% | ||
| Q4 24 | -62.4% | -69.2% | ||
| Q3 24 | -61.3% | -36.4% | ||
| Q2 24 | -56.8% | -90.8% | ||
| Q1 24 | -59.2% | -6.1% |
净利率GHRILY
| Q4 25 | -45.7% | 47.9% | ||
| Q3 25 | -35.0% | 42.3% | ||
| Q2 25 | -43.0% | 74.1% | ||
| Q1 25 | -46.8% | -5.1% | ||
| Q4 24 | -55.0% | -2.3% | ||
| Q3 24 | -56.3% | -126.1% | ||
| Q2 24 | -57.9% | -169.4% | ||
| Q1 24 | -68.2% | -18.7% |
每股收益（稀释后）GHRILY
| Q4 25 | $-1.01 | $2.78 | ||
| Q3 25 | $-0.74 | $2.91 | ||
| Q2 25 | $-0.80 | $4.50 | ||
| Q1 25 | $-0.77 | $-0.39 | ||
| Q4 24 | $-0.90 | $-0.01 | ||
| Q3 24 | $-0.88 | $-9.39 | ||
| Q2 24 | $-0.84 | $-14.35 | ||
| Q1 24 | $-0.94 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $378.2M | $226.6M |
| 总债务越低越好 | $1.5B | $1.4B |
| 股东权益账面价值 | $-99.3M | $-171.5M |
| 总资产 | $2.0B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GHRILY
| Q4 25 | $378.2M | $226.6M | ||
| Q3 25 | $580.0M | $184.2M | ||
| Q2 25 | $629.1M | $267.4M | ||
| Q1 25 | $698.6M | $138.3M | ||
| Q4 24 | $525.5M | $146.9M | ||
| Q3 24 | $585.0M | $159.2M | ||
| Q2 24 | $933.7M | $236.9M | ||
| Q1 24 | $1.0B | $190.7M |
总债务GHRILY
| Q4 25 | $1.5B | $1.4B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $1.1B | $1.4B | ||
| Q4 24 | $1.1B | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GHRILY
| Q4 25 | $-99.3M | $-171.5M | ||
| Q3 25 | $-354.5M | $-260.5M | ||
| Q2 25 | $-305.5M | $-351.7M | ||
| Q1 25 | $-250.8M | $-496.8M | ||
| Q4 24 | $-139.6M | $-488.2M | ||
| Q3 24 | $-60.1M | $-497.6M | ||
| Q2 24 | $-1.6M | $-218.3M | ||
| Q1 24 | $68.3M | $228.4M |
总资产GHRILY
| Q4 25 | $2.0B | $1.7B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.5B | $1.8B | ||
| Q3 24 | $1.5B | $2.2B | ||
| Q2 24 | $1.6B | $3.2B | ||
| Q1 24 | $1.7B | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.4M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $-54.2M | — |
| 自由现金流率自由现金流/营收 | -19.3% | — |
| 资本支出强度资本支出/营收 | 9.9% | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | $-233.1M | — |
8季度趋势，按日历期对齐
经营现金流GHRILY
| Q4 25 | $-26.4M | $26.2M | ||
| Q3 25 | $-35.4M | $-60.6M | ||
| Q2 25 | $-60.3M | $-25.6M | ||
| Q1 25 | $-62.7M | $184.0K | ||
| Q4 24 | $-64.5M | $-2.7M | ||
| Q3 24 | $-51.1M | $19.5M | ||
| Q2 24 | $-94.0M | $111.5M | ||
| Q1 24 | $-30.3M | $135.4M |
自由现金流GHRILY
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | — | ||
| Q2 25 | $-65.9M | — | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | — | ||
| Q1 24 | $-37.2M | — |
自由现金流率GHRILY
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | — | ||
| Q2 25 | -28.4% | — | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | — | ||
| Q1 24 | -22.1% | — |
资本支出强度GHRILY
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.9% | — | ||
| Q1 24 | 4.1% | — |
现金转化率GHRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
